I think worries about passing manufacturing are not in the drama queen bear category. I think you're flat out wrong, but there are many more moving parts than the typical biologic. Since manufacturing was a significant part of our first three meetings with the company, we've had a decade to become familiar and comfortable with it.
The CMC issues were minor (documentation, equipment barcodes missing) and would not have held up approval.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr